BMS-813160(BMS-813160) - 药物靶点：CCR2 x CCR5_在研适应症：肝细胞癌，非小细胞肺癌，晚期胰腺导管腺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

BMS 813160

靶点

CCR2 x CCR5

作用方式

拮抗剂

作用机制

CCR2拮抗剂(C-C趋化因子受体2型拮抗剂)、CCR5拮抗剂(C-C趋化因子受体5型拮抗剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [1]

在研适应症

肝细胞癌非小细胞肺癌晚期胰腺导管腺癌+ [1]

非在研适应症

晚期癌症晚期恶性实体瘤晚期肾细胞癌+ [5]

原研机构

Bristol Myers Squibb Co.

在研机构

Bristol Myers Squibb Co.

非在研机构-

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C25H40N8O2

InChIKeyCMVHFGNTABZQJU-HCXYKTFWSA-N

CAS号1286279-29-5

关联

7

项与 BMS-813160 相关的临床试验

NCT04123379

/ Active, not recruiting临床2期IIT

Tisch Cancer Institute - BMS Study # CA027-005: Neoadjuvant Nivolumab + BMS-813160 (CCR2/5-inhibitor) or BMS-986253 (anti-IL-8) for NSCLC or HCC

The purpose of this research study is to study the effect of giving nivolumab with CCR2/5-inhibitor or anti-IL-8 before surgery, and after surgery, with the goal of determining if this medicine results in:
1. A significant immune response against their tumor (which the study team will see in the tumor that is taken out at the time of surgery)
2. Improvement in long term survival rates

开始日期2020-03-05

申办/合作机构

Icahn School of Medicine at Mount Sinai

[+1]

NCT03767582

/ Completed临床1/2期IIT

A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs).

The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer (LAPC) who have received chemotherapy and radiotherapy, and to see if this combination therapy enhances the infiltration of CD8+CD137+ cells in PDACs .

开始日期2019-12-12

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

[+1]

NCT03496662

/ Completed临床1/2期IIT

A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

The purpose of this research study is to learn more about a new combination of drugs being given to treat pancreatic cancer. The drugs being tested are BMS-813160, nivolumab, gemcitabine, and nab-paclitaxel. The investigators will be looking at both the side effects and the way the disease responds to treatment.

开始日期2018-08-31

申办/合作机构

Washington University School of Medicine

[+4]

100 项与 BMS-813160 相关的临床结果

登录后查看更多信息

100 项与 BMS-813160 相关的转化医学

登录后查看更多信息

100 项与 BMS-813160 相关的专利（医药）

登录后查看更多信息

12

项与 BMS-813160 相关的文献（医药）

2023-01-01·Advanced biology

Macrophages in Tumor‐Associated Adipose Microenvironment Accelerate Tumor Progression

Article

作者: Liu, Siqing ; Sun, Shengrong ; Li, Bei ; Yang, Qian ; Wu, Qi ; Xu, Zhiliang ; Li, Zhiyu ; Sun, Si ; Li, Juanjuan ; Wu, Juan

Abstract:

Adipose‐tissue macrophages (ATMs), a complex ensemble of diverse macrophage subtypes, are prevalent in the tumor‐adipose microenvironment (TAME) and facilitate tumor growth. However, the mechanisms in which the tumor‐adipocyte crosstalk may enable the properties and plasticity of macrophages remain unclear. The single‐cell RNA‐sequence profiling reveals that a subset of macrophages expressed CD163, CCL2, and CCL5 in TAME, exhibiting an immunosuppressive subtype. It is demonstrated that CD163+ macrophages aggregate to surround adipocytes in breast cancer tissues. The expressions of CCL2 and CCL5 are also elevated in TAME and enable the recruitment and polarize macrophages. Mechanically, the level of exosomal miRNA‐155 increased in the coculture of tumor cells and adipocytes, and then it promoted the generation and release of CCL2 and CCL5 from adipocytes by targeting the SOCS6/STAT3 pathway. Inhibition of exosomal miRNA‐155 in tumor cells reduced the CCL2 and CCL5 levels in tumor‐adipocytes coculture and further retarded tumor growth. Finally, the deletion of macrophages partially inhibited adipocyte‐induced tumor proliferation. Likewise, inhibiting chemokines and their receptors or suppressing the phosphorylation of STAT3 decreased tumor burden in preclinical models. These results demonstrate that the niche factors in TAME, such as exosomal miRNA‐155, regulate the function and polarity of macrophages to facilitate tumor progression.

2022-11-01·TETRAHEDRON LETTERS

An azirine solid-state photodegradant of the CCR2/CCR5 dual antagonist BMS-813160

作者: Zang, Jia ; Fenster, Michael D. B. ; Hritzko, Benjamin ; Yuill, Elizabeth M. ; La Cruz, Thomas ; Sarjeant, Amy ; Ayers, Sloan ; Lin, Ziqing ; Zaretsky, Serge ; Huang, Yande ; Park, Hyunsoo ; Ramirez, Antonio

The synthesis of the CCR2/5 dual chemokine antagonist BMS-813160 (1) presented a number of interesting impurity and degradant structure elucidation challenges.This publication will focus on the structure elucidation of the solid-state photodegradant of 1 which produced an unexpected stable azirine species.The structure was elucidated by mass spectrometry and NMR, with confirmation by single-crystal X-ray crystallog.

2022-05-01·Journal of pharmaceutical and biomedical analysis3区 · 医学

Circumventing glass vial and diluent effects on solution stability of small molecule analytes during analytical method development and validation

3区 · 医学

Article

作者: Chadwick, James ; Marriott, Andrew S ; Huang, Yande ; Zang, Jia ; Miller, Scott A ; Hu, Yue ; Li, Jieming ; Yuill, Elizabeth M

Solution stability of analytes plays an important part in qualitative analysis, especially in conducting accurate, quantitative analyses. Sample diluents and glass vials as sample containers for HPLC analyses can play a critical role and should be evaluated during chromatographic method development. We have encountered several instances during pharmaceutical development where the glass vial/diluent combination has negatively impacted method performance. One case encompasses adsorption of piperazine, a secondary amine, to non-silanized glass vials, resulting in recovery failures during analytical method transfer. Two further cases describe the propensity for peracetylated C-aryl glucosides being subject chemical transformations relating to sample diluent. The first reports transesterification with methanol-based diluents and the second describes hydrolysis with acetonitrile/water diluents mediated by the mild alkalinity of certain brands of Type I borosilicate vials. A final case explores development of a related substance method, it was found that an impurity was prone to hydrolysis and another impurity with a primary amine tended to be adsorbed on glass vials. Diluents of appropriate pH and buffer strength were strategically selected to neutralize the mild alkalinity of the glass vials as well as to mitigate adsorption of the amine analyte on glass vials. As a result, excellent sample stability and reproducibility were achieved, regardless the quality and brand of Type I glass vials used. Here we present four case studies that demonstrate how the negative impact of Type I glass vials on those susceptible analytes can be effectively eliminated by using appropriate sample diluents, which is essential to ensure accurate analytical data and provide for a smooth method validation and transfer.

1

项与 BMS-813160 相关的新闻（医药）

2023-05-08

·PRNewswire

Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ Drugs

DUBLIN, May 8, 2023 /PRNewswire/ -- The "Pancreatic Cancer - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This "Pancreatic Cancer- Competitive landscape, 2023" report provides comprehensive insights about 250+ companies and 300+ drugs in Pancreatic Cancer Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. In March 2023, Adaptimmune Therapeutics plc. and TCR Therapeutics Inc. (NASDAQ: TCRR), announced entry into a definitive agreement under which Adaptimmune will combine with TCR in an all-stock transaction to create a preeminent cell therapy company focused on treating solid tumors. The combination provides extensive benefits for clinical development and product delivery supported by complementary technology platforms. As a result, and following the closing of the transaction, it is anticipated that the combined company's cash runway will extend into 2026. In February 2023, Akamis Bio, announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy (PICI) to include a clinical collaboration with the Cancer Research Institute (CRI) that will focus on advancing novel treatments for pancreatic cancer. As part of the Akamis Bio, PICI, and CRI partnership, NG-350A, an immuno-stimulatory tumor gene therapy driving intratumoral expression of a CD40 agonist monoclonal antibody, will be evaluated in combination with standard-of-care chemotherapy and the CTLA-4 inhibitor ipilimumab (YERVOY). In February 2023, Gritstone bio, Inc. announced that it has entered into a clinical trial agreement with the National Cancer Institute (NCI), an institute of the National Institutes of Health, to evaluate an autologous T cell therapy expressing a T cell receptor targeting mutated KRAS in combination with Gritstone's KRAS-directed vaccine candidate, SLATE-KRAS, in a Phase 1 study. Under the terms of the agreement, NCI will identify patients with metastatic cancer that are eligible for adoptive cell transfer based on the presence of a G12V or G12D KRAS mutation (KRASmut). In February 2023, Keymed Biosciences Inc., jointly announced a global exclusive license agreement with AstraZeneca for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC). Under the license agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialization of CMG901 globally. CMG901 is currently in a Phase I clinical trial for the treatment of Claudin 18.2-positive solid tumors. In January 2023, AIM ImmunoTech Inc. announced it has entered into an external sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca. Under the agreement, Erasmus MC is planning to perform an investigator-initiated clinical study, entitled "Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy effect. DURIPANC Study," in which it will use both Study Drugs provided by AstraZeneca and AIM ImmunoTech. Pancreatic Cancer Analytical Perspective In-depth Commercial Assessment: Pancreatic Cancer Collaboration Analysis by Companies The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form. Key Questions Answered Current Treatment Scenario and Emerging Therapies: How many companies are developing Pancreatic Cancer drugs? How many Pancreatic Cancer drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pancreatic Cancer? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pancreatic Cancer therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Pancreatic Cancer and their status? What are the key designations that have been granted to the emerging and approved drugs? Key Players Panbela Therapeutics ERYtech Pharma Jiangsu HengRui Medicine Co., Ltd. FibroGen Novartis AG AB Science TME Pharma AG Intensity Therapeutics Silenseed LTD SynerGene Therapeutics Elevation oncology Salspera LLC Redx Pharma Plc AIM ImmunoTech Inc. Rain Oncology Jazz Pharmaceuticals Invyte Corporation Immodulon Therapeutics Ltd GSK plc Merck Sharp & Dohme LLC Roche Helsinn Healthcare SA Argenus Inc. Actuate Therapeutics OSE Immunotherapeutics Incyte Corporation Galera Therapeutics CSPC ZhongQi Pharmaceutical Technology Astellas Pharma Global Development, Inc. NanOlogy Theriva Biologics AstraZeneca Berg, LLC Agenus ABVC BioPharma, Inc. Boehringer Ingelheim Alligator Bioscience CARsgenTherapeutics Co.,Ltd Purple Biotech Ltd. Lisata Therapeutics Chongqing Precision Biotech Co., Ltd Cybrexa Therapeutics Bold Therapeutics BioNTech SE Bristol-Myers Squibb DEKA Biosciences Senhwa Biosciences Cue Biopharma Carisma Therapeutics Inc Key Products Olaptesed pegol INT230-6 SBP-101 Masitinib NIS793 siG12D LODER SGT-53 Seribantumab Salmonella-IL2 RXC004 Rintatolimod RAIN-32 Lurbinectedin Retifanlimab IMM-101 GSK2256098 Belzutifan Atezolizumab Anamorelin AGEN1423 Elraglusib OSE2101 Epacadostat GC4711 Docetaxel Zolbetuximab NanoPac VCN-01 Danvatirsen BPM31510 Botensilimab ABV-1703 BI 907828 Mitazalimab CT041 CM24 CEND-1 CEA-targeted CAR-T cells CBX-12 BOLD-100 BNT141 BMS-813160 DK210 CX-5461 CUE-102 CT-0508 For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

免疫疗法引进/卖出疫苗临床1期抗体药物偶联物

100 项与 BMS-813160 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16240

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝细胞癌	临床2期	美国	Bristol Myers Squibb Co.	2020-03-05
非小细胞肺癌	临床2期	美国	Bristol Myers Squibb Co.	2020-03-05
晚期胰腺导管腺癌	临床2期	美国	Bristol Myers Squibb Co.	2019-12-12
局部晚期胰腺腺癌	临床2期	美国	Bristol Myers Squibb Co.	2019-12-12
晚期恶性实体瘤	临床2期	美国	Bristol Myers Squibb Co.	2017-08-08
晚期恶性实体瘤	临床2期	澳大利亚	Bristol Myers Squibb Co.	2017-08-08
晚期恶性实体瘤	临床2期	比利时	Bristol Myers Squibb Co.	2017-08-08
晚期恶性实体瘤	临床2期	加拿大	Bristol Myers Squibb Co.	2017-08-08
晚期恶性实体瘤	临床2期	德国	Bristol Myers Squibb Co.	2017-08-08
晚期恶性实体瘤	临床2期	西班牙	Bristol Myers Squibb Co.	2017-08-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO_IO2023	临床2期	肝细胞癌 \| 非小细胞肺癌	36	Nivolumab + BMS-813160 (CCR2/5i)	網膚壓夢願簾衊襯鏇壓(艱遞襯鹹壓夢襯憲願製) = 襯積衊製齋憲獵醖夢窪網觸製窪壓壓艱選壓繭 (膚蓋鹽選餘醖窪壓鑰網 )	-	2023-12-07
NCT03767582 (ASCO_GI2023) 人工标引	临床1期	胰腺导管腺癌	13	Nivolumab 480mg+BMS-813160 150mg/300mg+GVAX 5x108 cells	網獵鏇簾鏇獵夢膚鹽蓋(衊鹽壓艱夢壓鏇艱餘夢) = 淵襯簾衊鹽餘繭鬱襯鏇糧廠遞鹽構夢醖獵製膚 (憲艱顧遞壓壓衊鹽窪願 ) 更多	积极	2023-01-24
NCT03496662 (CTgov)	临床1/2期	胰腺导管腺癌	40	Peripheral blood+Nivolumab+nab-paclitaxel+Gemcitabine+BMS-813160 (Part A - Experimental Dose Level 0)	築憲鑰憲網醖餘鹽積鹽 = 製製構鑰遞憲製簾淵齋壓蓋夢窪齋選觸繭觸窪 (鑰鑰遞鏇壓醖顧觸獵餘, 範鬱淵淵構糧網廠餘積 ~ 壓齋遞糧壓膚網網衊製) 更多	-	2022-11-30
NCT03496662 (CTgov)	临床1/2期	胰腺导管腺癌	40	Peripheral blood+Nab-paclitaxel+Gemcitabine (Part A - Control (Chemotherapy Only))	顧窪遞願鏇網膚簾簾積(選憲願觸積鹹觸遞鑰遞) = 鑰淵鑰廠範淵壓憲窪淵膚構鏇淵夢鹽鑰糧憲繭 (蓋繭選衊築構淵齋膚鏇, 衊衊壓膚簾構夢鬱鑰積 ~ 獵壓淵獵選簾積廠選襯) 更多	-	2022-11-30
NCT01752985 (CTgov)	临床2期	2型糖尿病 \| 糖尿病肾病	319	BMS-813160 (BMS-813160 150 mg QD)	簾鬱鑰夢壓顧壓廠願構(構網鹽糧衊簾顧積網積) = 鑰艱膚鑰鑰鏇築壓衊淵鹹餘襯鑰襯艱積築糧網 (築壓鹽鏇膚醖築餘獵繭, 48.994) 更多	-	2019-06-25
NCT01752985 (CTgov)	临床2期	2型糖尿病 \| 糖尿病肾病	319	BMS-813160 (BMS-813160 300 mg BID)	簾鬱鑰夢壓顧壓廠願構(構網鹽糧衊簾顧積網積) = 窪襯範壓鏇鑰淵襯鑰憲鹹餘襯鑰襯艱積築糧網 (築壓鹽鏇膚醖築餘獵繭, 62.795) 更多	-	2019-06-25